EFFECTS OF HORMONAL THERAPY IN TRANSGENDERS

A ARSHAD; M ATIF; M HUZAIFA; MM TAYYAB; B RAFIQ; MLA KHAN; MN SHAHID

doi:10.54112/bcsrj.v2024i1.948

Authors

A ARSHAD Lahore University of Management Sciences (LUMS), Pakistan
M ATIF Department of Pathology, Cholistan University of Veterinary and Animal Sciences Bahawalpur-63100, Pakistan
M HUZAIFA Department of Pathology, Cholistan University of Veterinary and Animal Sciences Bahawalpur-63100, Pakistan
MM TAYYAB Department of Pathology, Cholistan University of Veterinary and Animal Sciences Bahawalpur-63100, Pakistan
B RAFIQ 3Department of Microbiology, Cholistan University of Veterinary and Animal Sciences Bahawalpur-63100, Pakistan
MLA KHAN Department of Pathology, Cholistan University of Veterinary and Animal Sciences Bahawalpur-63100, Pakistan
MN SHAHID Department of Pathology, Cholistan University of Veterinary and Animal Sciences Bahawalpur-63100, Pakistan

DOI:

https://doi.org/10.54112/bcsrj.v2024i1.948

Keywords:

Bone Density,, Cardiovascular Disorders,, Hormonal Imbalance,, Hormonal Therapy,, Transgender Persons,

Abstract

People who change their gender after birth are known as transgender people. They underwent surgical transformation along with hormonal therapy. Hormonal imbalance is the most common phenomenon in the transgender community due to hormonal therapy and other related issues. Hormonal therapy is essential for gender transformation, but this therapy poses several risks to the individual who is taking this therapy. Transgender people who are under hormonal therapy are more at risk of cardiovascular disorders as certain hormones like estrogen and testosterone, besides their intended function, also induce side effects, due to which individuals taking these hormones become more prone to cardiovascular disorder, irregular blood pressure, brain function, and structure start changing. The cross-sex hormone therapy is also associated with brain tumors, changes in body mass index, and several skin conditions. Such hormones also affect bone density in different individuals due to changes in the deposition pattern of calcium into the bone under hormonal control. Hormonal therapy causes certain metabolic disorders as well, and certain hormones interact with other hormones in a different way when they are not naturally produced in the body. The voice of such people undergoing gender transformation also changes due to the testosterone level. This review summarizes some aspects of hormonal therapy, but whether or not a person undergoes such transition is their choice.

Downloads

Download data is not yet available.

References

Reiman, A., Ocasio, T. & Mezzapelle, J. How Cisgender People Define “Transgender” Is Associated with Attitudes Toward Transgender People. (2022).

Chrisler, J. C. & Pryzgoda, J. Definitions of gender and sex: The subtleties of meaning. Sex Roles 43, 553–569 (2000).

Norton, A. T. & Herek, G. M. Heterosexuals’ Attitudes Toward Transgender People: Findings from a National Probability Sample of U.S. Adults. Sex Roles 68, 738–753 (2013).

Buck, D. M. Defining transgender: What do lay definitions say about prejudice? Psychol. Sex. Orientat. Gend. Divers. 3, 465–472 (2016).

Ittiphisit, S., Amponnavarat, S., Manaboriboon, N. & Korpaisarn, S. The Real-World Characteristics of Gender-Affirming Hormonal Use Among Transgender People in Thailand. Sex. Med. 10, 100513 (2022).

Pyra, M. et al. An observational study of hypertension and thromboembolism among transgender patients using gender-affirming hormone therapy. Transgender Heal. 5, 1–9 (2020).

Ristori, J. et al. Hormonal Treatment Effect on Sexual Distress in Transgender Persons: 2-Year Follow-Up Data. J. Sex. Med. 17, 142–151 (2020).

Klaver, M. et al. Early Hormonal Treatment Affects Body Composition and Body Shape in Young Transgender Adolescents. J. Sex. Med. 15, 251–260 (2018).

Hembree, W. C. et al. Endocrine treatment of transsexual persons: An endocrine society clinical practice guideline. J. Clin. Endocrinol. Metab. 94, 3132–3154 (2009).

Wierckx, K. et al. Long-Term Evaluation of Cross-Sex Hormone Treatment in Transsexual Persons. J. Sex. Med. 9, 2641–2651 (2012).

van Heesewijk, J. O. et al. Long-Term Gender-Affirming Hormone Therapy and Cognitive Functioning in Older Transgender Women Compared With Cisgender Women and Men. J. Sex. Med. 18, 1434–1443 (2021).

Roberts, T. K. et al. Interpreting laboratory results in transgender patients on hormone therapy. Am. J. Med. 127, 159–162 (2014).

Sam, K. Q., Severs, F. J., Ebuoma, L. O., Chandandeep, N. S. & Sedgwick, E. L. Granulomatous mastitis in a transgender patient. J. Radiol. Case Rep. 11, 16–22 (2017).

Nota, N. M. et al. Occurrence of acute cardiovascular events in transgender individuals receiving hormone therapy: results from a large cohort study. Circulation 139, 1461–1462 (2019).

Defreyne, J. et al. Vaginal bleeding and spotting in transgender men after initiation of testosterone therapy: A prospective cohort study (ENIGI). Int. J. Transgender Heal. 21, 163–175 (2020).

Ahmad, S. & Leinung, M. The response of the menstrual cycle to initiation of hormonal therapy in transgender men. Transgender Heal. 2, 176–179 (2017).

Seiger, R. et al. Subcortical gray matter changes in transgender subjects after long-term cross-sex hormone administration. Psychoneuroendocrinology 74, 371–379 (2016).

Rametti, G. et al. Effects of androgenization on the white matter microstructure of female-to-male transsexuals. A diffusion tensor imaging study. Psychoneuroendocrinology 37, 1261–1269 (2012).

Claus, E. B. et al. Epidemiology of intracranial meningioma. Neurosurgery 57, 1088–1095 (2005).

Knight, E. J. & McDonald, M. J. Recurrence and Progression of Meningioma in Male-to-Female Transgender Individuals During Exogenous Hormone Use. Int. J. Transgenderism 14, 18–23 (2013).

Hancock, A. B. & Garabedian, L. M. Transgender voice and communication treatment: A retrospective chart review of 25 cases. Int. J. Lang. Commun. Disord. 48, 54–65 (2013).

Kadakia, S., Carlson, D. & Sataloff, R. The Effect of Hormones on the Voice. J. Singing-The Off. J. Natl. Assoc. Teach. Sing. 69, 571–574 (2013).

Gray, M. L. & Courey, M. S. Transgender Voice and Communication. Otolaryngol. Clin. North Am. 52, 713–722 (2019).

Cundill, P. Hormone therapy for trans and gender diverse patients in the general practice setting. Aust. J. Gen. Pract. 49, 385–390 (2020).

T’Sjoen, G. et al. Prevalence of Low Bone Mass about Estrogen Treatment and Body Composition in Male-to-Female Transsexual Persons. J. Clin. Densitom. 12, 306–313 (2009).

Lapauw, B. et al. Body composition, volumetric and areal bone parameters in male-to-female transsexual persons. Bone 43, 1016–1021 (2008).

Gooren, L. & Lips, P. Conjectures concerning cross-sex hormone treatment of aging transsexual persons. J. Sex. Med. 11, 2012–2019 (2014).

Stevenson, M. O., Wixon, N. & Safer, J. D. Scalp Hair Regrowth in Hormone-Treated Transgender Woman. Transgender Heal. 1, 202–204 (2016).

Wamboldt, R., Haseeb, S., Waddington, A. & Baranchuk, A. Cardiac arrhythmias secondary to hormone therapy in trans women. Expert Rev. Cardiovasc. Ther. 17, 335–343 (2019).

Streed, C. G. et al. Cardiovascular Disease Among Transgender Adults Receiving Hormone Therapy. Ann. Intern. Med. 167, 256 (2017).

Aranda, G. et al. Effects of sex steroids on cardiovascular risk profile in transgender men under gender affirming hormone therapy. Endocrinol. Diabetes y Nutr. (English ed.) 66, 385–392 (2019).

Wierckx, K. et al. Long‐term evaluation of cross‐sex hormone treatment in transsexual persons. J. Sex. Med. 9, 2641–2651 (2012).

Slack, D. J. & Safer, J. D. Cardiovascular Health Maintenance in Aging Individuals: The Implications for Transgender Men and Women on Hormone Therapy. Endocr. Pract. 27, 63–70 (2021).

Cocchetti, C. et al. Does Gender-Affirming Hormonal Treatment Affect 30-Year Cardiovascular Risk in Transgender Persons? A Two-Year Prospective European Study (ENIGI). J. Sex. Med. 18, 821–829 (2021).

Alzahrani, T. et al. Cardiovascular disease risk factors and myocardial infarction in the transgender population. Circ. Cardiovasc. Qual. Outcomes 12, 1–7 (2019).

Getahun, D. et al. Cross-sex hormones and acute cardiovascular events in transgender persons: A cohort study. Ann. Intern. Med. 169, 205–213 (2018).

Martinez, C. et al. Gender Identity, Hormone Therapy, and Cardiovascular Disease Risk. Curr. Probl. Cardiol. 45, (2020).

Wierckx, K. et al. Prevalence of cardiovascular disease and cancer during cross-sex hormone therapy in a large cohort of trans persons: A case-control study. Eur. J. Endocrinol. 169, 471–478 (2013).

Høibraaten, E., Abdelnoor, M. & Sandset, P. M. Hormone Replacement Therapy with Estradiol and Risk of Venous Thromboembolism. Thromb. Haemost. 82, 1218–1221 (1999).

Asscheman, H., Gooren, L. J. G. & Eklund, P. L. E. Mortality and morbidity in transsexual patients with cross-gender hormone treatment. Metabolism 38, 869–873 (1989).

Asscheman, H. et al. A long-term follow-up study of mortality in transsexuals receiving treatment with cross-sex hormones. Eur. J. Endocrinol. 164, 635–642 (2011).

Hembree, W. C. et al. Endocrine treatment of gender-dysphoric/ gender-incongruent persons: An endocrine society∗clinical practice guideline. J. Clin. Endocrinol. Metab. 102, 3869–3903 (2017).

Quirós, C. et al. Effect of cross-sex hormone treatment on cardiovascular risk factors in transsexual individuals. Experience in a specialized unit in Catalonia. Endocrinol. y Nutr. 62, 210–216 (2015).

Arnold, J. D., Sarkodie, E. P., Coleman, M. E. & Goldstein, D. A. Incidence of Venous Thromboembolism in Transgender Women Receiving Oral Estradiol. J. Sex. Med. 13, 1773–1777 (2016).

Gooren, L. J., Wierckx, K. & Giltay, E. J. Cardiovascular disease in transsexual persons treated with cross-sex hormones: Reversal of the traditional sex difference in cardiovascular disease pattern. Eur. J. Endocrinol. 170, 809–819 (2014).

Giltay, E. J., Gooren, L. J. G., Emeis, J. J., Kooistra, T. & Stehouwer, C. D. A. Lowers Tissue-Type Plasminogen Activator Levels in. 1396–1403 (2000).

Kotamarti, V. S., Greige, N., Heiman, A. J., Patel, A. & Ricci, J. A. Risk for Venous Thromboembolism in Transgender Patients Undergoing Cross-Sex Hormone Treatment: A Systematic Review. J. Sex. Med. 18, 1280–1291 (2021).

Peña Barreno, C., Gonzalez-Peramato, P. & Nistal, M. Vascular and inflammatory effects of estrogen and anti-androgen therapy in the testis and epididymis of male to female transgender adults. Reprod. Toxicol. 95, 37–44 (2020).

Gooren, L. J., Giltay, E. J. & Bunck, M. C. Long-term treatment of transsexuals with cross-sex hormones: Extensive personal experience. J. Clin. Endocrinol. Metab. 93, 19–25 (2008).

Tangpricha, V. & den Heijer, M. Oestrogen and anti-androgen therapy for transgender women. Lancet Diabetes Endocrinol. 5, 291–300 (2017).

Barsoum, M. K. et al. Is progestin an independent risk factor for incident venous thromboembolism? A population-based case-control study. Thromb. Res. 126, 373–378 (2010).

Perl, L. et al. Blood pressure dynamics after pubertal suppression with gonadotropin-releasing hormone analogs followed by estradiol treatment in transgender female adolescents: A pilot study. J. Pediatr. Endocrinol. Metab. 34, 741–745 (2021).

Banks, K. et al. Blood Pressure Effects of Gender-Affirming Hormone Therapy in Transgender and Gender-Diverse Adults. Hypertension 2066–2074 (2021) doi:10.1161/HYPERTENSIONAHA.120.16839.

Wanhong, H., Misra, G., Tang, L., Ruixuan, W. & Sheng-Xiang, L. 乳鼠心肌提取 HHS Public Access. Gene 588, 54–61 (2016).

Dhejne, C. et al. Long-term follow-up of transsexual persons undergoing sex reassignment surgery: Cohort study in Sweden. PLoS One 6, (2011).

Klaver, M. et al. Hormonal treatment and cardiovascular risk profile in transgender adolescents. Pediatrics 145, (2020).

Kulprachakarn, K., Ounjaijean, S., Rerkasem, K., Molinsky, R. L. & Demmer, R. T. Cardiovascular disease risk factors among transgender women in Chiang Mai, Thailand. Am. J. Cardiovasc. Dis. 10, 124–130 (2020).

Palumbo, P. et al. In vitro evaluation of different methods of handling human liposuction aspirate and their effect on adipocytes and adipose derived stem cells. J. Cell. Physiol. 230, 1974–1981 (2015).

Tofler, G. H. et al. Effects of gender and race on prognosis after myocardial infarction: Adverse prognosis for women, particularly black women. J. Am. Coll. Cardiol. 9, 473–482 (1987).

Zubiaurre-Elorza, L. et al. The Effects of Testosterone on the Brain of Transgender Men. Androgens 2, 252–260 (2021).

Schmidt, E. & Rizzolo, D. transgender and gender-diverse adults. (2020) doi:10.1097/01.JAA.0000524709.87224.57.

Mohammadi, M. R. & Khaleghi, A. Transsexualism : A Different Viewpoint to Brain Changes. 16, 136–143 (2018).

Kranz, G. S., Zhang, B. B. B., Handschuh, P., Ritter, V. & Lanzenberger, R. Gender-affirming hormone treatment – A unique approach to study the effects of sex hormones on brain structure and function. Cortex 129, 68–79 (2020).

Hulshoff Pol, H. E. et al. Changing your sex changes your brain: Influences of testosterone and estrogen on adult human brain structure. in European Journal of Endocrinology, Supplement vol. 155 107–114 (2006).

Hahn, A. et al. Structural connectivity networks of transgender people. Cereb. Cortex 25, 3527–3534 (2015).

Burke, S. M. et al. Testosterone Effects on the Brain in Transgender Men. Cereb. Cortex 28, 1582–1596 (2018).

Zubiaurre-Elorza, L., Junque, C., Gómez-Gil, E. & Guillamon, A. Effects of cross-sex hormone treatment on cortical thickness in transsexual individuals. J. Sex. Med. 11, 1248–1261 (2014).

Seiger, R. et al. Subcortical gray matter changes in transgender subjects after long-term cross-sex hormone administration. Psychoneuroendocrinology 74, 371–379 (2016).

Handschuh, P. A. et al. Effects of gender-affirming hormone therapy on gray matter density, microstructure and monoamine oxidase A levels in transgender subjects. medRxiv vol. 43 1–31 (2022).

Nota, N. M. et al. The occurrence of benign brain tumours in transgender individuals during cross-sex hormone treatment. Brain 141, 2047–2054 (2018).

Bergoglio, M. T., Gómez-Balaguer, M., Almonacid Folch, E., Hurtado Murillo, F. & Hernández-Mijares, A. Symptomatic meningioma induced by cross-sex hormone treatment in a male-to-female transsexual. Endocrinol. y Nutr. 60, 264–267 (2013).

Raven, L. M. & Christopher, M. G. Hyperprolactinemia and association with prolactinoma in transwomen receiving gender af fi rming hormone treatment Case series. Endocrine 2–6 (2021) doi:10.1007/s12020-020-02563-3.

Kleinschmidt-DeMasters, B. K. Pituitary adenomas in transgender individuals? J. Neuropathol. Exp. Neurol. 79, 62–66 (2020).

Mundluru, S. N. & Larson, A. R. Medical dermatologic conditions in transgender women. Int. J. Women’s Dermatology 4, 212–215 (2018).

Motosko, C. C., Zakhem, G. A., Pomeranz, M. K. & Hazen, A. Acne: a side-effect of masculinizing hormonal therapy in transgender patients. Br. J. Dermatol. 180, 26–30 (2019).

Ginsberg, B. A., Calderon, M., Seminara, N. M. & Day, D. A potential role for the dermatologist in the physical transformation of transgender people: A survey of attitudes and practices within the transgender community. J. Am. Acad. Dermatol. 74, 303–308 (2016).

Dhingra, N., Bonati, L. M., Wang, E. B., Ba, M. C. & Ms, J. J. Medical and aesthetic procedural dermatology recommendations for transgender patients undergoing transition. J. Am. Dermatology 1–10 (2019) doi:10.1016/j.jaad.2018.05.1259.

Boos, M. D., Bs, N. H. & Hodax, J. K. Management of acne in transgender and gender diverse youth part 1 : Gender affirming care and risk factors for the development of acne. 1–4 (2022) doi:10.1111/pde.15113.

Fighera, T. M., Ziegelmann, P. K., Rasia da Silva, T. & Spritzer, P. M. Bone mass effects of cross-sex hormone therapy in transgender people: updated systematic review and meta-analysis. J. Endocr. Soc. 3, 943–964 (2019).

Delgado-Ruiz, R., Swanson, P. & Romanos, G. Systematic review of the long-term effects of transgender hormone therapy on bone markers and bone mineral density and their potential effects in implant therapy. J. Clin. Med. 8, 1–21 (2019).

Wiepjes, C. M. et al. Bone Safety During the First Ten Years of Gender-Affirming Hormonal Treatment in Transwomen and Transmen. J. Bone Miner. Res. 34, 447–454 (2019).

Wiepjes, C. M. et al. Bone geometry and trabecular bone score in transgender people before and after short- and long-term hormonal treatment. Bone 127, 280–286 (2019).

Pelusi, C. et al. Effects of three different testosterone formulations in female-to-male transsexual persons. J. Sex. Med. 11, 3002–3011 (2014).

Wiepjes, C. M. et al. Bone Mineral Density Increases in Trans Persons After 1 Year of Hormonal Treatment: A Multicenter Prospective Observational Study. J. Bone Miner. Res. 32, 1252–1260 (2017).

Unger, C. A. Hormone therapy for transgender patients. Translational Andrology and Urology vol. 5 (2016).

Jr, R. J. F. Gender-Affirming Hormone Therapy for Transgender Females. Clin. Obstet. Gynecol. 61, 705–721 (2018).

van Velzen, D. M. et al. The effect of transgender hormonal treatment on high density lipoprotein cholesterol efflux capacity. Atherosclerosis 323, 44–53 (2021).

Fernandez, J. D. & Tannock, L. R. Metabolic effects of hormone therapy in transgender patients. Endocr. Pract. 22, 383–388 (2016).

Radix, A. Hormone Therapy for Transgender Adults. Urol. Clin. North Am. 46, 467–473 (2019).

SoRelle, J. A. et al. Impact of hormone therapy on laboratory values in transgender patients. Clin. Chem. 65, 170–179 (2019).

Allen, A. N. et al. Dynamic impact of hormone therapy on laboratory values in transgender patients over time. J. Appl. Lab. Med. 6, 27–40 (2021).

Auer, M. K. et al. Effects of sex hormone treatment on the metabolic syndrome in transgender individuals: Focus on metabolic cytokines. J. Clin. Endocrinol. Metab. 103, 790–802 (2018).

Shadid, S. et al. Effects of gender-affirming hormone therapy on insulin sensitivity and incretin responses in transgender people. Diabetes Care 43, 411–417 (2020).

Wiik, A. et al. Metabolic and functional changes in transgender individuals following cross-sex hormone treatment: Design and methods of the GEnder Dysphoria Treatment in Sweden (GETS) study. Contemp. Clin. Trials Commun. 10, 148–153 (2018).

Van Velzen, D. M. et al. Cardiometabolic effects of testosterone in transmen and estrogen plus cyproterone acetate in transwomen. J. Clin. Endocrinol. Metab. 104, 1937–1947 (2019).

Fisher, A. D. et al. Cross-sex hormone treatment and psychobiological changes in transsexual persons: Two-year follow-up data. J. Clin. Endocrinol. Metab. 101, 4260–4269 (2016).

Kyinn, M. et al. Weight gain and obesity rates in transgender and gender-diverse adults before and during hormone therapy. Int. J. Obes. 45, 2562–2569 (2021).

Nygren, U., Nordenskjöld, A., Arver, S. & Södersten, M. Effects on Voice Fundamental Frequency and Satisfaction with Voice in Trans Men during Testosterone Treatment—A Longitudinal Study. J. Voice 30, 766.e23-766.e34 (2016).

Ainsworth, T. A. & Spiegel, J. H. Quality of life of individuals with and without facial feminization surgery or gender reassignment surgery. Qual. Life Res. 19, 1019–1024 (2010).

Defreyne, J. et al. Sexual Desire Changes in Transgender Individuals Upon Initiation of Hormone Treatment: Results From the Longitudinal European Network for the Investigation of Gender Incongruence. J. Sex. Med. 17, 812–825 (2020).

Village, S. Research Article. 8, 42–48 (2020).

Castilo, D. & João, T. L. Application of low Intensity laser Associated with Exercise with High-Strength Tube in the Vocal Treatment of Transgender Women: Pilot Study. J. Clin. Biomed. Res. 2, 1–6 (2020).

Chen, D. et al. Multidisciplinary Care for Gender-Diverse Youth: A Narrative Review and Unique Model of Gender-Affirming Care. Transgender Heal. 1, 117–123 (2016).

Venegas, C. O., Garrido, F. M. & Muñoz, L. D. Vocal self-perception in Spanish-speaking Trans Women from Santiago: the first study in Chile. Rev. Chil. Fonoaudiol. 20, 1–8 (2021).

Schneider, M. A. et al. Brain maturation, cognition and voice pattern in a gender dysphoria case under pubertal suppression. Front. Hum. Neurosci. 11, 1–9 (2017).

Tassinari, R. & Maranghi, F. Rodent model of gender-affirming hormone therapies as specific tool for identifying susceptibility and vulnerability of transgender people and future applications for risk assessment. Int. J. Environ. Res. Public Health 18, (2021).

I, A. B., District, B. & Bengal, W. Doctor of Philosophy Doctor of Philosophy. 1–7 (2012).

Bultynck, C., Cosyns, M., T’Sjoen, G., Van Borsel, J. & Bonte, K. Thyroplasty Type III to Lower the Vocal Pitch in Trans Men. Otolaryngol. - Head Neck Surg. (United States) 164, 157–159 (2021).